RxDoctor Payments Data

Matthew McDiarmid, DO

Interventional Cardiology · Thornton, CONPI 1003234162

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (43.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Philips North America LLC at 29.8% of the total.

$52,137in general payments, 2019–2025

Across 650 payments — averaging $80.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$16K
  • Penumbra, Inc.$8K
  • Medtronic$3K
  • Boston Scientific$3K
  • Angiodynamics, Inc.$3K
  • Inari Medical, Inc.$2K
  • plus $18K from 54 others

What the payments were for

  • Consulting fees$1,0482%
  • Speaking & faculty fees$11,86323%
  • Grants$1,6413%
  • Travel & lodging$10,23920%
  • Food & beverage$22,86244%
  • Education$1,7693%
  • Other$2,7155%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Philips North America LLC39$15,534
Penumbra, Inc.25$8,014
Medtronic(2 entities)48$2,939
Boston Scientific21$2,904
Angiodynamics, Inc.5$2,875
Inari Medical, Inc.27$2,195
Abbott31$2,129
Abiomed22$1,646
Bard Peripheral Vascular, Inc.16$1,383
Actelion Pharmaceuticals US, Inc.57$913
E.r. Squibb & Sons, L.L.C.35$758
Terumo Medical Corporation2$700
Edwards Lifesciences10$680
Heartflow, Inc.26$660
Shockwave Medical, Inc6$646
Impulse Dynamics (USA) Inc.9$595
Kestra Medical Technology Services, Inc.17$517
Cagent Vascular Inc4$509
Amgen22$477
Pfizer23$451
Bayer19$419
Cardiovascular Systems Inc.3$393
Novartis18$392
Johnson & Johnson21$369
Endologix LLC5$348
Novo Nordisk15$348
BD2$330
Astellas Pharma US Inc3$270
Esperion Therapeutics, Inc.13$224
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)14$219
Boehringer Ingelheim10$212
Merck9$170
Cvrx, Inc.8$165
W. L. Gore & Associates, Inc.2$147
Alnylam Pharmaceuticals Inc.5$131
AstraZeneca7$127
Biotronik Inc.1$108
Mozarc Medical US LLC1$96
Scpharmaceuticals Inc.5$93
Bridgebio Pharma, Inc.3$83
Kiniksa Pharmaceuticals International, PLC4$83
United Therapeutics Corporation3$69
Regeneron Healthcare Solutions, Inc.2$65
Tempus AI, Inc1$62
Cleerly, Inc.3$60
Akcea Therapeutics, Inc.1$59
Veryan Medical Incorporated1$54
Cardiva Medical, Inc.2$47
Irhythm Technologies, Inc.1$46
Baxter Healthcare2$45
Lexicon Pharmaceuticals, Inc.3$43
Lilly USA, LLC2$43
Kiniksa Pharmaceuticals, Ltd.2$40
Sanofi-aventis U.S. LLC2$29
Smith+Nephew1$26
Ossur Americas, Inc.1$26
Recor Medical Inc1$22
Biowound Solutions, Inc.1$20
CSL Behring1$19
Atricure, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,137 in reported general payments places this provider in the 85th percentile of 111 interventional cardiology providers in Colorado.

See all interventional cardiology providers in Colorado

Medicare billing

Part B allowed, 2024
$356,798
Medicare patients
408
Services billed
3,643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$78,782
FarxigaDapagliflozin Propanediol53$52,572
XareltoRivaroxaban44$38,917
JardianceEmpagliflozin41$35,525
BrilintaTicagrelor42$32,899
EntrestoSacubitril/Valsartan23$31,733
Repatha SyringeEvolocumab18$10,071
Repatha SureclickEvolocumab15$8,322
Prasugrel Hcl38$2,317
ClopidogrelClopidogrel Bisulfate130$961
Carvedilol120$847
Metoprolol Tartrate175$760
Atorvastatin Calcium114$743
Lisinopril84$503
Rosuvastatin Calcium50$449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$127$85,47295 claims
PfizerEliquis$451$78,78268 claims
Johnson & JohnsonXarelto$369$38,91744 claims
Boehringer IngelheimJardiance$212$35,52541 claims
NovartisEntresto$392$31,73323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 111 interventional cardiology providers in Colorado.

Other interventional cardiology in Thornton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →